ANNOTATIONS

ORAL ADMINISTRATION OF BISTOVOL IN GENERAL PARALYSIS

Bistovol (basic bismuth acetylaminohydroxyphenyl arsonate) is a compound of bismuth and stovarsol (acetarsol sodium). The compound is obtainable in tablets for oral use.

According to Levaditi, and to Levaditi and Fournier, some of the bismuth appears in the urine after the oral administration of Bistovol; hence it offers a convenient method of combining stovarsol and bismuth therapy without resource to injections.

Since July 1927 it has been the routine at this hospital to treat general paralysis with malaria, supplemented by the administration of pentavalent organic arsenicals. In 1936 oral stovarsol took the place of tryparsamide, and during the eight-year period 1937-1944 the oral preparation of Bistovol has been used. The last-mentioned compound has been given initially in nearly every case for several alternate weeks prior to inoculation with malaria, the daily dosage being one tablet (4 grains) less than the patient's weight in stones (for example, 2 tablets 4 times a day on alternate weeks for a patient weighing 9 stone 5 pounds). The dose was reduced or omitted in the occasional cases in which dermatitis developed, and such patients were given ascorbic acid.

The optimal period for chemotherapy with Bistovol prior to the use of malaria therapy appeared to be about 3 months, since patients showed no further mental or physical improvement if this period were exceeded. Debilitated cases either died during this period or recovered sufficiently to tolerate 8 malarial rigors.

The clinical results attributable to Bistovol alone have been similar to those previously published with regard to stovarsol (Pakenham-Walsh and Rennie), but the cell counts in the cerebrospinal fluid were more rapidly reduced by the former. Unlike stovarsol, Bistovol has been well tolerated by the gastro-intestinal

TABLE 1.—GENERAL PARALYSIS OF THE INSANE: ADMISSIONS, RECOVERIES, AND DEATHS AT LANCASTER.

METHODS OF TREATMENT							
Tryparsamide and malaria				Bistovol and malaria			
Year	Number of patients			Year	Number of patients		
	Admitted	Recovered	Died		Admitted	Recovered	Died
1928 ...	20	0	28	1937 ...	24	7	13
1929 ...	14	0	10	1938 ...	30	4	10
1930 ...	14	5	15	1939 ...	23	6	9
1931 ...	33	0	20	1940 ...	19	6	11
1932 ...	28	1	17	1941 ...	26	8	12
1933 ...	33	9	18	1942 ...	14	4	7
1934 ...	31	3	15	1943 ...	16	4	6
1935 ...	28	3	23	1944 ...	16	5	5
Totals ...	201	21	146	Totals ...	168	44	73
Recovery and death rates		10 per cent	73 per cent	Recovery and death rates		26 per cent	43 per cent

tract, provided that not more than 2 tablets are given simultaneously at intervals of at least 2 hours.

In Table 1, the eight-year period during which Bistovol was used at Lancaster in conjunction with malaria therapy is compared with another eight-year period during which malaria was supplemented by tryparsamide. Unfortunately a large number of patients in the tryparsamide group received malaria therapy initially, and many of these died before the chemotherapy had been given a

ANNOTATIONS

chance to produce its effect. Hence the obvious improvement in the Bistovol group does not indicate any superiority of Bistovol over tryparsamide. On the other hand, if an inert substance had been given to the majority of patients for several weeks prior to inoculation, the delay would have been deleterious. The figures therefore suggest that Bistovol is therapeutically active when given by mouth.

In Tables 2 and 3 an attempt has been made to study the relative values of Bistovol and tryparsamide by means of the serological changes which follow the

TABLE 2—EFFECT OF BISTOVOL ON THE PARETIC FORMULA

BEFORE TREATMENT				INTERVAL	AFTER TREATMENT			
W.R. C.S.F.	Protein mg. %	Lange reaction	Cells per c.mm.	No. of weeks	W.R. C.S.F.	Protein mg. %	Lange reaction	Cells per c.mm.
++	55	5555433210	8	9	—	30	0113220000	3
+++	90	5554432100	210	9	+++	60	5555554200	2
+++	40	5543100000	6	11	++†	40	3454420000	2
+++	100	5555543210	14	12	+++	100	5544421000	3
+++	50	5555543100	20	13	++†	45	0121100000	2
+++	80	5555543100	60	13	++	90	5554432100	7
++†	140	5555555420	18	13	†	60	1343310000	4
+++	85	5554433200	33	15	+++	40	5443310000	4
+++	80	5553100000	24	16	±	40	5544210000	3
++†	70	5554210000	9	16	+++	65	1123100000	3
+++	80	5555554310	209	16	+++	30	5554310000	4
+++	160	5555555421	75	17	++†	80	4443321000	4
+++	80	5555543100	21	17	+++	70	5554431000	5
+++	75	5555543000	36	17	+++	50	5543100000	2
++†	210	5555432100	38	20	†	70	1111110000	4
+++	140	5555542100	31	20	++†	50	5555430000	4
+++	120	5554432000	55	22	+++	60	5543211000	2
++	80	5555543200	20	24	±	45	0135420000	2
+++	100	5555554310	16	31	++†	40	2344320000	2
+++	120	5555555421	25	31	+++	80	5444433100	3

W.R. } = Wassermann reaction of cerebrospinal fluid
C.S.F. }

administration of these compounds over approximately the same periods of time.

The serological results given in Table 2 have been recorded in 20 cases of general paralysis, in which each of the patients exhibited a typical paretic formula prior to the commencement of treatment. The second readings were taken 9–31 weeks after the first, Bistovol having been given exclusively during the interval.

Table 3 (after Tennent) shows the effect of 15–37 injections of 3 grammes of tryparsamide in 10 cases of general paralysis. As the injections were given weekly and the second puncture was made “at the end of each course of treatment”, it is evident that the intervals approximate to those of Table 2.

Comment on Tables 2 and 3

The Wassermann test.—Although the same method of recording has not been used throughout, it is evident that more than half the number of cases in each group have shown a weakening after treatment.

The protein content.—After treatment the average is 57 milligrams per cent

in Table 2 and 56 milligrams per cent in Table 3, despite the fact that the initial averages are 98 and 125 milligrams per cent respectively.

The Lange reaction.—Some of the curves, notably the last in each series, have remained resistant to treatment. This is not surprising, since Hinrichsen states in a review on tryparsamide that 100–150 injections of tryparsamide may be required to produce changes in the colloidal gold curve. The first tube result was a “five” in 55 per cent of my cases after the administration of Bistovol

TABLE 3—EFFECT OF TRYPARSAMIDE ON THE PARETIC FORMULA

BEFORE TREATMENT				TREATMENT	AFTER TREATMENT			
W.R. C.S.F.	Protein mg. %	Lange Reaction	Cells per c.mm.	No. of Injections	W.R. C.S.F.	Protein mg. %	Lange reaction	Cells per c.mm.
+40+	100	5443210000	50	15	+20+	35	0000000000	5
+40+	180	5555543210	100	16	+40	80	4434222110	37
+40+	125	5555543211	50	21	+40+	75	55555432110	10
+40+	125	5555554321	78	22	+40	80	5544321000	40
+ 8+	125	5555543200	80	24	+ 8+	45	2223331100	5
+40+	130	5555543210	50	24	+40+	80	5553322100	28
+40+	125	5555543210	80	28	+ 8	45	0011100000	5
+20+	50	5555543210	18	28	+ 4	30	0000000000	5
+40+	200	5555543210	100	35	+ 4+	35	3332211000	4
+20+	90	5555554400	50	37	+ 3+	55	5554321100	3

W.R.
C.S.F. } = Wassermann reaction of cerebrospinal fluid

and in 40 per cent of Tennent's cases after tryparsamide medication.

The cells.—The reduction in the cell count is more consistent in the Bistovol series.

Conclusions

(1) The introduction of oral Bistovol as an adjuvant to the malarial treatment of general paralysis has coincided with a favourable alteration in the statistical tables of this hospital.

(2) Oral Bistovol has been specially suitable for the “building up” of debilitated patients, who would otherwise have been unfit to undergo malarial treatment.

(3) Oral Bistovol has an effect on the paretic formula comparable to that of tryparsamide. It produces a more rapid reduction in the cell count than does tryparsamide or stovarsol.

(4) From the point of view of ease of administration and relative absence of toxic effect, oral Bistovol is preferable to tryparsamide and stovarsol.

(5) Further research is required in order to decide whether or not the penicillin treatment of general paralysis, now in vogue (Goldman), will displace the former methods or be used in conjunction with them.

I wish to thank Dr. J. D. Silverston, Medical Superintendent of the hospital, for permission to publish this paper, and also Prof. H. B. Maitland for the reports on the Wassermann reactions.

County Mental Hospital,
Lancaster

R. PAKENHAM-WALSH, D.M., D.P.M.

REFERENCES

- Goldman, D. (1945) *J. Amer. med. Ass.*, 128, 274.
Hinrichsen, J. (1939) *J. vener. Dis. Inform.*, 20, 293.
Levaditi, C. (1928) *Brit. J. vener. Dis.*, 4, 25.
— and Fournier, L. (1928) *Lancet*, 1, 692.
Pakenham-Walsh, R., and Rennie, A. T. (1937) *Lancet*, 1, 982.
Tennent, T. (1931) *J. ment. Sci.*, 77, 86.